PresentationPresentation A Phase 1 Study of Selinexor in Combination with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers PDF (738.99 KB) Read MorePresentation First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL PDF (3.83 MB) Read MorePresentation Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin PDF (3.25 MB) Read MorePresentation Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma PDF (908.32 KB) Read MorePresentation Single Agent Oral Selinexor in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Phase 2b SADAL Study PDF (4.14 MB) Read MorePresentation Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer PDF (507.62 KB) Read MorePresentation Phase 1B Study to Evaluate the Safety of Selinexor in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies PDF (1.02 MB) Read MorePresentation The Enhancement of Anti-Tumor Activities of Selinexor when Combined with Immune Checkpoint Inhibitors PDF (9.27 MB) Read MorePresentation Phase 2 Study of Selinexor in Patients with MDS Refractory to Hypomethylating Agents: Interim Report PDF (1.45 MB) Read MorePresentation Selinexor or KPT-8602 Mediated XPO1 Inhibition Synergizes with Dexamethasone to Repress Convergent Pathways in the mTORC1 Signaling Network and Drive Cell Death in Multiple Myeloma PDF (1.06 MB) Read More Previous 1 2 3 4 5 … 15 Next